危重症患者体内的促红细胞生成素——其作用是否不止于血液方面？
Erythropoietin in the critically ill - is it more than just blood?
作者信息
Corwin Howard L
机构信息
Dartmouth Medical School, Lebanon, New Hampshire, USA.
出版信息
Crit Care. 2004 Oct;8(5):325-6. doi: 10.1186/cc2949. Epub 2004 Sep 6.
Abstract
Erythropoietin (EPO) has been in clinical use for the treatment of anemia for over 15 years. Recently it has been demonstrated that EPO has actions other than stimulating the bone marrow. It has been suggested that due to its tissue protecting effect, EPO may be effective in improving outcome in the critically ill.
摘要
促红细胞生成素（EPO）已在临床用于治疗贫血超过15年。最近有研究表明，EPO除了刺激骨髓外还有其他作用。有人提出，由于其组织保护作用，EPO可能对改善危重症患者的预后有效。
相似文献
1
Erythropoietin in the critically ill - is it more than just blood?危重症患者体内的促红细胞生成素——其作用是否不止于血液方面？
Crit Care. 2004 Oct;8(5):325-6. doi: 10.1186/cc2949. Epub 2004 Sep 6.
2
The role of erythropoietin therapy in the critically ill.促红细胞生成素疗法在危重症患者中的作用。
Transfus Med Rev. 2006 Jan;20(1):27-33. doi: 10.1016/j.tmrv.2005.08.002.
3
Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy.促红细胞生成素在需要肾脏替代治疗的急性肾衰竭危重症患者中的应用。
Am J Kidney Dis. 2005 Nov;46(5):791-8. doi: 10.1053/j.ajkd.2005.07.034.
4
Erythropoietin in the critically ill: what is the evidence?危重症患者中的促红细胞生成素：证据有哪些？
Nephrol Dial Transplant. 2005 Dec;20(12):2605-8. doi: 10.1093/ndt/gfh970. Epub 2005 Oct 12.
5
Anemia and red blood cell transfusion in the critically ill.危重症患者的贫血与红细胞输注
Semin Dial. 2006 Nov-Dec;19(6):513-6. doi: 10.1111/j.1525-139X.2006.00214.x.
6
Anaemia in the critically ill patient: monitoring of erythropoietin therapy.
BJU Int. 2006 Jun;97(6):1161-4. doi: 10.1111/j.1464-410X.2006.06172.x.
7
Alternatives to blood product transfusion in the critically ill: erythropoietin.危重症患者血液制品输注的替代方法：促红细胞生成素。
Crit Care Med. 2006 May;34(5 Suppl):S160-9. doi: 10.1097/01.CCM.0000214290.11479.5C.
8
Can erythropoietin eradicate red cell transfusions in the critically ill?促红细胞生成素能消除危重症患者的红细胞输注需求吗？
Crit Care Med. 2006 Sep;34(9):2490-1. doi: 10.1097/01.CCM.0000235671.59923.CF.
9
Response to the randomized trial of recombinant human erythropoietin in critically ill patients.重组人促红细胞生成素用于重症患者的随机试验的结果
Crit Care Med. 2007 Jun;35(6):1632. doi: 10.1097/01.CCM.0000266837.49803.D0.
10
Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.促红细胞生成素介导的组织保护：减少原发性损伤反应的附带损害。
J Intern Med. 2008 Nov;264(5):405-32. doi: 10.1111/j.1365-2796.2008.02024.x.
引用本文的文献
1
Acute kidney injury in the elderly population.老年人群中的急性肾损伤。
Int Urol Nephrol. 2010 Mar;42(1):259-71. doi: 10.1007/s11255-009-9629-7. Epub 2009 Aug 26.
本文引用的文献
1
Science review: recombinant human erythropoietin in critical illness: a role beyond anemia?科学综述：重组人促红细胞生成素在危重症中的作用：是否超越了贫血范畴？
Crit Care. 2004 Oct;8(5):337-41. doi: 10.1186/cc2897. Epub 2004 Jun 16.
2
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.促红细胞生成素α。一种多效细胞因子的临床演变。
Arch Intern Med. 2004 Feb 9;164(3):262-76. doi: 10.1001/archinte.164.3.262.
3
Erythropoietin is a multifunctional tissue-protective cytokine.促红细胞生成素是一种多功能的组织保护细胞因子。
Curr Hematol Rep. 2003 Nov;2(6):465-70.
4
The problems and challenges of immunotherapy in sepsis.脓毒症免疫治疗的问题与挑战。
Chest. 2003 May;123(5 Suppl):451S-9S. doi: 10.1378/chest.123.5_suppl.451s.
5
The pathophysiology and treatment of sepsis.脓毒症的病理生理学与治疗
N Engl J Med. 2003 Jan 9;348(2):138-50. doi: 10.1056/NEJMra021333.
6
The immunopathogenesis of sepsis.脓毒症的免疫发病机制。
Nature. 2002;420(6917):885-91. doi: 10.1038/nature01326.
7
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.重组人促红细胞生成素对危重症患者的疗效：一项随机对照试验。
JAMA. 2002 Dec 11;288(22):2827-35. doi: 10.1001/jama.288.22.2827.
8
Erythropoietin therapy for acute stroke is both safe and beneficial.促红细胞生成素治疗急性中风既安全又有益。
Mol Med. 2002 Aug;8(8):495-505.
9
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.促红细胞生成素可穿过血脑屏障，以预防实验性脑损伤。
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10526-31. doi: 10.1073/pnas.97.19.10526.
10
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.皮下注射促红细胞生成素和静脉注射铁剂用于治疗重度难治性充血性心力衰竭的贫血，可改善心脏和肾功能以及心功能分级，并显著减少住院次数。
J Am Coll Cardiol. 2000 Jun;35(7):1737-44. doi: 10.1016/s0735-1097(00)00613-6.
Zotero 插件